
Pleryon Therapeutics
China · Biotech & life sciences · Series A

NEOCRETE
New Zealand · Deep tech & materials · Seed
Compatibility /100
50/100
High potentialWhy talk
- Complementary sectors: Biotech & life sciences × Deep tech & materials — room for a joint offer or co-selling.
- Pleryon Therapeutics is one step ahead of NEOCRETE (Seed): Pleryon Therapeutics can share its playbook.
- NEOCRETE likely needs funding for the next round — Pleryon Therapeutics can offer investor introductions (inferred from public profile).
Score anatomy
Each segment is what one dimension adds, out of 100.
Score by goal
Dimension by dimension
Needs ↔ offers
5.0 / 10 pts
Pleryon Therapeutics can help NEOCRETE.
- NEOCRETE likely needs funding for the next round — Pleryon Therapeutics can offer investor introductions (inferred from public profile).
Market bridge
2.5 / 10 pts
Distant markets.
- NEOCRETE is based in New Zealand (Oceania): a landing pad on another continent, both ways.
Customer potential
2.8 / 5 pts
Some customer potential.
- NEOCRETE already has first customers in a related sector (Deep tech & materials): Activator used at commercial scale by Readymix Brunei (case study).
Sector synergy
25.0 / 50 pts
Complementary sectors.
- Complementary sectors: Biotech & life sciences × Deep tech & materials — room for a joint offer or co-selling.
Stage complementarity
15.0 / 25 pts
Useful peer or mentor link.
- Pleryon Therapeutics is one step ahead of NEOCRETE (Seed): Pleryon Therapeutics can share its playbook.
How the score works
Each dimension gives a value between 0 and 1, multiplied by its weight; the compatibility is the sum (0–100). Weights for “Peers”: Needs ↔ offers 10, Market bridge 10, Customer potential 5, Sector synergy 50, Stage complementarity 25. Declared needs and offers count fully; when a startup has declared nothing, a few needs/offers are inferred from its public profile (for example, no known traction ⇒ needs customers) and count at half value.
Potential blends compatibility (65%) with the mean global score of both startups (35%): 52/100 — high from 50, medium from 36.